When examining the latest trends in the treatment of Alzheimer, the paradigm has been shifted to immunotherapy through the activation of macrophage in the brain from the present target therapy in which accumulation of amyloid  or tau protein phosphorylation in the brain directly targeted. In particular, the attention of the industry and the academy is paid that when administrating anti-PD-1 or anti-PD-L1 antibodies, which are immunotherapy drugs, these activated macrophages infiltrate to the brain, and the effect of treating Alzheimer's disease by directly removing amyloid-beta by macrophages has been confirmed.

Our investigational immunotherapy CB201 targets immune cells in the brain, and has been shown to activate immune cells in Alzheimer’s disease-induced animal models. It was confirmed that CB201 promotes the differentiation of monocytes into monocyte-derived macrophages and activates microglia, and these activated immune cells remove Alzheimer’s-inducing substances accumulated in the brain to treat Alzheimer’s disease and improve memory and behavioral functions.

In animal studies, our compound CB201 was tested on two types of Alzheimer’s-induced mice. In the first model (5xFAD), our immunotherapeutic drug CB201 restored the Alzheimer's disease model to 85% of that of normal mice in the 'Y-maze experiment (Y-maze), and it was verified that the decline of cognition, memory, and behavioral abilities due to Alzheimer's dementia were restored to almost the same level as normal mice by improving to 106% compared to normal mice in the Morris water maze experiment (Morris water maze). (Ref. : Biomedicines, 2025) In the second model (APP/PS1), CB201 demonstrated recovery of memory and cognitive functions in both the Morris water maze test (for long-term memory, learning, and motor function) and the fear conditioning test (for short-term memory and cognition), bringing performance close to that of normal mice. Furthermore, brain tissue analysis of CB201-treated mice confirmed that Alzheimer’s-associated pathological substances were effectively cleared, demonstrating symptom improvement and therapeutic efficacy.

CB201 being developed by CentricsBio activates the immune function of the brain and removes the causative agent, expected to be effective not only in Alzheimer's but also in other degenerative brain diseases. The research to expand the therapy area proceeds and we would like to Improve the quality of life with immunotherapeutic agents that show new possibilities for the treatment of degenerative brain diseases.